Publication date: 21/11/2018
Mithra (Euronext Brussels: MITRA) announces that it has reduced the environmental impact of its CDMO facility in Belgium with the installation of 1800 solar panels. Mithra has also put in place an internal committee within its CDMO with the aim of reducing costs and minimizing the environmental impact of the company’s manufacturing activities.
Thanks to the current and future investments, which will have no impact on budget, the CDMO is aiming to secure approximately 50% of its electricity consumption through a renewable energy source, allowing Mithra to reduce its carbon footprint and reduce a major cost driver of the Mithra CDMO. New renewable energy alternatives are also being considered to further reduce operational expenses.
Mithra’s state-of-the-art production and R&D facility (CDMO) was first opened in 2016 and incorporates strict environmental considerations into its GMP equipment and infrastructure in terms of air treatment, containment measures, modern solutions for energy monitoring and choice of reusable consumables. Additional environmental measures undertaken by Mithra’s CDMO include energy monitoring on all electricity, water, heat and chillers to optimize consumption, implementation of a day/night mode for air flow management, and a water retention system for water recycling. These measures are improved on a continuous basis.
François Fornieri, CEO of Mithra Women’s Health commented: “As a company, Mithra is fully committed to sustainable development and reducing our environmental footprint. The installation of 1800 solar panels is a further step to achieving this goal and will significantly contribute to the overall reduction of Mithra’s environmental impact. We have also put together an internal committee, which we believe will lead to further environmental initiatives across the business.”
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com